Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oncolytic Virus in Recurrent Glioblastoma
NCT07145047Phase 2Recruiting
- Sponsor
- Mianyang Central Hospital
- Start
- Nov 2023
- Primary completion
- Dec 2025
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in glioblastoma (GBM), sponsored by Mianyang Central Hospital. Primary endpoint: Maximum tolerated dose at 14 days. Started Nov 2023; status: recruiting.
02
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT07145047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07145047.